Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032708 · ClinicalTrials.gov registry record · Phase 2
Dryvax Dilution-Prev Vacc Adults
A Phase 2 study of Smallpox, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT00032708: Completed Phase 2 study of Smallpox, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00032708 is a Phase 2 study of Smallpox that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 90 participants, below the 131,039-participant average among 7 other Smallpox trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00032708, a Phase 2 study of Smallpox, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
A double-blind, randomized, dose-response study of four dilutions of Dryvax in previously vaccinated adults in order to assess the clinical success rates, humoral responses, and virus-specific actifity of cytotoxi T cells and interferon-y producing T cells
Conditions Studied
Interventions
- BIOLOGICAL Dryvax
Study Locations (1)
Missouri
- Saint Louis University Health Sciences Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2004-04 |
| Est. Completion | 2004-11 |
| Phase | Phase 2 |
What the finished NCT00032708 record still lists
NCT00032708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 131,039-participant average among 7 other Smallpox trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Smallpox appearing as the primary indexed condition, and to 1 intervention - of which Dryvax is the first listed.
NCT00032708 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT00032708 about?
NCT00032708 is a clinical study titled "Dryvax Dilution-Prev Vacc Adults". A double-blind, randomized, dose-response study of four dilutions of Dryvax in previously vaccinated adults in order to assess the clinical success rates, humoral responses, and virus-specific actifity of cytotoxi T cells and interferon-y producing T cells
What is the current status of trial NCT00032708?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2004-04. Estimated completion is 2004-11.
What conditions does trial NCT00032708 study?
This clinical trial studies the following conditions: Smallpox.
What interventions are being tested in trial NCT00032708?
The interventions under investigation include: Dryvax (BIOLOGICAL).
Who is sponsoring clinical trial NCT00032708?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00032708 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smallpox
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
ACTIVE NOT RECRUITING · Phase 2
-
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally
COMPLETED · Phase 2
-
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
COMPLETED · Phase 2
-
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
COMPLETED
-
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
COMPLETED
-
Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia